Media Center

SEVERAL INNOVATIVE DRUGS AND NEW INDICATIONS FROM HANSOH PHARMA WERE INCLUDED IN THE 2022 NATIONAL REIMBURSABLE DRUG LIST

HANSOH PHARMA'S CD19 MAB XINYUE OPENS A NEW ERA OF REIMBURSABLE DRUGS FOR RARE DISEASE NMOSD

HANSOH PHARMA: EQRX'S MARKETING AUTHORIZATION APPLICATION FOR AUMOLERTINIB FOR THE TREATMENT OF NSCLC WITH EPIDERMAL GROWTH FACTOR MUTATIONS WAS ACCEPTED BY THE EMA

INNOVATIVE DRUGS CONTRIBUTE TO ONE HALF OF ITS REVENUE; IN-HOUSE R&D AND EXTERNAL BD COLLABORATION BOTH ENTER THE FAST LANE - WHAT'S BEHIND THIS PHARMACEUTICAL COMPANY'S SUCCESS?

PLACE LESS EMPHASIS ON GENERIC DRUGS AND CENTRALIZED PROCUREMENT AND MORE EMPHASIS ON R&D - HANSOH PHARMA IS ACCELERATING ITS TRANSFORMATION

HANSOH PHARMA'S HENGMU ENTERED THE LIST OF "THE 14TH HEALTHY CHINA FORUM · TOP 10 NEW DRUGS"

AMBRISENTAN LOCALIZED: CHINA APPROVES FIRST-TO-MARKET AMBRISENTAN GENERIC (PUNUOAN) OF HANSOH PHARMA

INNOVATIVE ONCOLOGY DRUG BREAKS FOREIGN MONOPOLY